Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
ZUMA-1 demonstrated a high rate of durable response and a manageable safety profile with axicabtagene ciloleucel (axi-cel), an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in patients with refractory large B-cell lymphoma. As previously reported, prespecified clinical covariates for secondary end point analysis were not clearly predictive of efficacy; these included Eastern Cooperative Oncology Group performance status (0 vs 1), age, disease subtype, disease stage, and International Prognostic Index score. We interrogated covariates included in the statistical analysis plan and an extensive panel of biomarkers according to an expanded translational biomarker plan. Univariable and multivariable analyses indicated that rapid CAR T-cell expansion commensurate with pretreatment tumor burden (influenced by product T-cell fitness), the number of CD8 and CCR7+CD45RA+ T cells infused, and host systemic inflammation, were the most significant determining factors for durable response. Key parameters differentially associated with clinical efficacy and toxicities, with both theoretical and practical implications for optimizing CAR T-cell therapy. This trial was registered at www.clinicaltrials.gov as #NCT02348216.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“High tumor burden is associated with poorer outcomes after axi-cel therapy.37,60”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [60]
The cited source says what the claim attributes to it.
In the citing paper
“the dose of reinfused CAR-T cells has been suggested to influence clinical outcomes [32, 33].”
From Harmonisation of quality control tests for academic production of CAR-T cells: a position paper from the WP-bioproduction of the UNITC consortium (2025) · cites this paper as [33]
In the citing paper
“The recently reported ZUMA-1 trial biomarker analysis showed that patients with high tumor burden (measured on conventional computed tomography imaging) required greater CAR T-cell expansion to generate durable responses.60”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [60]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030 · cited 5×
“Safety and efficacy results were previously reported.(7) Durable response referred to patients who were in ongoing response at least 1 year after axi-cel infusion.”
BackgroundMethodResultSelf-citationRevised Response Criteria for Malignant Lymphoma
Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,426
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112 · cited 3×
“Despite high clinical efficacy, approximately 60% of patients do not respond to or relapse within 2 years of treatment with axi-cel or other anti-CD19 CAR T-cell therapies.(6,8) Mechanisms associated with durable responses remain incompletely elucidated, and previous correlative analyses have largely focused on toxici…”
BackgroundResultUnbiased Recursive Partitioning: A Conditional Inference Framework
Hothorn, T., Hornik, K., & Zeileis, A. (2006) · Journal of Computational and Graphical Statistics · doi:10.1198/106186006x133933 · Cited by 4,021
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Self-citationCurrent concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806 · cited 1×
“These toxicities are generally reversible and manageable with supportive therapy, corticosteroids, and interleukin-6R (IL-6R) blockade.(7,12,13) Despite high clinical efficacy, approximately 60% of patients do not respond to or relapse within 2 years of treatment with axi-cel or other anti-CD19 CAR T-cell therapies.”
BackgroundChimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438
Self-citationLocke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30864-7 · Cited by 2,286 · cited 6×
“This study builds extensively on earlier findings with key product attributes and patient and tumor characteristics.(6,8,9,19,49) To our knowledge, this represents the most extensive covariate analysis of its kind: several variables were examined on a relatively large uniform patient population treated with a specific…”
BackgroundResultSelf-citationCD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
Couzin-Frankel, J. (2013) · Science · doi:10.1126/science.342.6165.1432 · Cited by 2,051
Research works printed but not linked: 1
- Arihara, 2019, Deep phenotypic and functional analysis of transduced anti-CD19 CAR T cells and untransduced T cells in patients treated with axi-cel by single cell mass cytometry [abstract], J Immunother Cancer, 7
Cited by
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
Locke, F. L., Miklos, D. B., Jacobson, C. A., Perales, M.-A., Kersten, M.-J., Oluwole, O. O., Ghobadi, A., Rapoport, A. P., McGuirk, J., Pagel, J. M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116133 · Cited by 1,607
Self-citationClinical implications of T cell exhaustion for cancer immunotherapy
Chow, A., Perica, K., Klebanoff, C. A., & Wolchok, J. D. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00689-z · Cited by 1,044
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
Bishop, M. R., Dickinson, M., Purtill, D., Barba, P., Santoro, A., Hamad, N., Kato, K., Sureda, A., Greil, R., Thieblemont, C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116596 · Cited by 538
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
Albelda, S. M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00832-4 · Cited by 517
“In this regard, the observation that the CD19-targeted CAR T cell products with the highest clinical efficacy in patients with chronic lymphocytic leukaemia or B cell lymphoma are those with the highest proportion of naive-like and central memory (CCR7 + ) cells is not surprising 95–97 .”
BackgroundMarin, D., Li, Y., Basar, R., Rafei, H., Daher, M., Dou, J., Mohanty, V., Dede, M., Nieto, Y., Uprety, N., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02785-8 · Cited by 516
Metadata
- Authors
- Locke, F. L., Rossi, J. M., Neelapu, S. S., Jacobson, C. A., Miklos, D. B., Ghobadi, A., Oluwole, O. O., Reagan, P. M., Lekakis, L. J., Lin, Y., Sherman, M., Better, M., Go, W. Y., Wiezorek, J. S., Xue, A., & Bot, A.
- Affiliations
- Moffitt Cancer Center (US)
- Kite (United States) (US)
- The University of Texas MD Anderson Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- Stanford Medicine (US)
- Washington University in St. Louis (US)
- Vanderbilt University (US)
- University of Rochester Medicine (US)
- University of Miami Health System (US)
- Mayo Clinic (US)
- ORCID
- Venue
- Blood Advances
- Publisher
- American Society of Hematology
- Published
- 2020-10-09
- Volume
- 4
- Issue
- 19
- Pages
- 4898-4911
- ISSN
- 2473-9529 (ISSN-L)
- 2473-9537
- PMC
- PMC7556133
- OpenAlex
- W3092023747
- Cited by
- 489
- References
- 52
- Citations by year
- 2026: 74 · 2025: 90 · 2024: 88 · 2023: 102 · 2022: 68 · 2021: 62 · 2020: 2
- FWCI
- 21.12
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Blood Advances (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- Funders
- Gilead Sciences
- National Institutes of Health (UL1TR003167)
- National Cancer Institute (K23CA201594)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- axicabtagene ciloleucel, large B-cell lymphoma, CAR T-cell therapy, anti-CD19, tumor burden, systemic inflammation, CD8+ T cells, T cell fitness, durable response, prognostic factors, ZUMA-1, treatment toxicity
- MeSH terms
- Biological Products, Humans, Inflammation, Immunotherapy, Adoptive, Antigens, CD19, Tumor Burden
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. https://app.cochat.ai/papers/10.1182/bloodadvances.2020002394
- The paper
- Locke, F. L., Rossi, J. M., Neelapu, S. S., Jacobson, C. A., Miklos, D. B., Ghobadi, A., Oluwole, O. O., Reagan, P. M., Lekakis, L. J., Lin, Y., Sherman, M., Better, M., Go, W. Y., Wiezorek, J. S., Xue, A., & Bot, A. (2020). Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Advances. https://doi.org/10.1182/bloodadvances.2020002394
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.